How will digital technologies impact disease management and healthcare over the next decade?
Find out in the just-released whitepaper, "The Digital Medicine Crystal Ball: Unlocking the Future of Real-Time, Precise, Effective, Healthcare."
The last five years have seen an unprecedented eruption in technological and health advances.
These new technologies and products—many undergoing rigorous clinical validation—will have significant direct impacts on diagnosing, preventing, monitoring or treating a disease, condition or syndrome, which in turn will transform disease management and alter business models across industries.
This whitepaper describes the current and future influence of digital medicine on the health ecosystem and highlights how various stakeholders are working to deliver clinically impactful and economically viable solutions in a saturated yet still-emerging business environment.
Topics addressed in the whitepaper include:
How various stakeholders are working to deliver clinically impactful and economically viable solutions in a saturated yet still-emerging business environment
The new roles of traditional healthcare players
How the entrance of new technologies will affect partnership models and business strategies
The future of digital medicine’s regulatory environment
The report, produced by EBD Group in collaboration with Hogan Lovells, and authored by Forbes contributor, Nicole Fisher, features insights from Evidation Health, Hogan Lovells, J&J Innovation, NIH/PMI, Sanofi, StartUp Health, and key opinion leaders such as John Nosta and Unity Stoakes.
Meet innovative companies in this emerging field as well as potential collaborators featured in this whitepaper at Digital Medicine Connect, a one-day partnering event taking place during BioPharm America™ on September 15, 2016. Learn more.